User profiles for "author:Vivek Subbiah"
Vivek Subbiah, MDAssociate Professor, The University of Texas MD Anderson Cancer Center Verified email at mdanderson.org Cited by 25169 |
[HTML][HTML] The next generation of evidence-based medicine
V Subbiah - Nature medicine, 2023 - nature.com
Recently, advances in wearable technologies, data science and machine learning have
begun to transform evidence-based medicine, offering a tantalizing glimpse into a future of …
begun to transform evidence-based medicine, offering a tantalizing glimpse into a future of …
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
[HTML][HTML] Clinical development of BRAF plus MEK inhibitor combinations
V Subbiah, C Baik, JM Kirkwood - Trends in cancer, 2020 - cell.com
Genomic profiling shows that many solid tumors are characterized by specific driver
aberrations, and this has expanded the therapeutic options for many patients. The mitogen …
aberrations, and this has expanded the therapeutic options for many patients. The mitogen …
[HTML][HTML] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …
histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation …
[HTML][HTML] Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer
V Subbiah, RJ Kreitman, ZA Wainberg… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib
(MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a …
(MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a …
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …
[HTML][HTML] Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …
[HTML][HTML] Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
V Subbiah, RJ Kreitman, ZA Wainberg, A Gazzah… - Nature medicine, 2023 - nature.com
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
PY Wen, A Stein, M van den Bent, J De Greve… - The lancet …, 2022 - thelancet.com
Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
[HTML][HTML] Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
LJ Wirth, E Sherman, B Robinson… - … England Journal of …, 2020 - Mass Medical Soc
Background RET mutations occur in 70% of medullary thyroid cancers, and RET fusions
occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the …
occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the …